CA15-3 Detection Service

Creative Biolabs is a leading service provider that focuses on tumor-associated glycan detection. Based on our advanced platforms and extensive experience, now we can provide the novel CA15-3 detection service for the diagnostic of breast cancer for our clients all over the world.

CA15-3 in Breast Cancer

Breast cancer is one of the most common cancers among women and also the second most common cancer worldwide. Since the 5-year survival rate of breast cancer is highly dependent on the tumor stage, its early detection can provide more treatment options and improve treatment conditions.

Studies have shown that changes in glycosylation are an important sign of cancer progression and abnormal glycosylation is a sensitive indicator of carcinogenesis. CA15-3 is a transmembrane protein with variable numbers of tandem repeats of peptides modified by glycosylation. As a heavily glycosylated protein, the glycosylation changes of CA15-3 in breast cancer have become the most extensive serum biomarker index.

Fig 1. Schematic diagram of the antibody-lectin sandwich assay. Immobilized anti-CA15-3 antibody captures CA15-3 in serum, and glycosylation of CA15-3 is detected with a biotinylated lectin followed by HRP-conjugated streptavidin. (Choi, 2018)

Techniques for CA15-3 Detection in Breast Cancer

In recent years, a series of diagnostic techniques including mammography, magnetic resonance imaging, positron emission tomography, and biopsy have been widely used for patients with breast cancer. However, these techniques are always limited by features such as expensive, time-consuming, and low detection efficiency. In this case, serum biomarkers detection has been served as an ideal diagnostic technique to improve survival and increase the detection rate of early cancer.

Using two types of anti-CA15-3 monoclonal antibodies, the sandwich enzyme-linked immunosorbent assay (ELISA) has been used for serum CA15-3 detection. During this test, the target glycoprotein special antibodies immobilized on the 96-well plate will capture the serum glycoprotein, and the glycosylation can be detected by the lectin. With Concanavalin A (ConA) lectin, when the serum is diluted to 2000 times, a good linear response can still be obtained. In the ELISA test, we also found that the glycosylation level of CA15-3 increases as the stage of breast cancer increases. In this case, breast cancer can be staged according to this system

Lectin blotting can also be used for CA15-3 glycosylation detection. After diluting and transferring the immunoprecipitate, the mannosylated N-glycosylation of CA15-3 can be detected with biotinylated ConA (1 µg/ml), followed by poly-HRP-conjugated streptavidin (1:10,000).

Creative Biolabs has been a long-term expert in the field of glycomics research. As a pioneer and the undisrupted global leader in tumor-associated glycan detection, we offer a variety of solutions to improve your productivity and streamline your research processes. If you are interested in our products or services, please do not hesitate to contact us for more detailed information.

Reference

1. Choi, J.; et al. Use of CA15‑3 for screening breast cancer: An antibody‑lectin sandwich assay for detecting glycosylation of CA15‑3 in sera. Oncology reports. 2018, 40(1): 145-154.

Related Services:

1. CA125 Detection Service
2. CA19-9 Detection Service
3. CA72-4 Detection Service
4. Prostate-specific Antigen (PSA) Detection Service
5. CEA Detection Service
6. Mucin Detection Service